Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 9/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD4 | P21917 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | TGM2 | P21980 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | RRM1 | P23921 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13660685 | 0.95 | POLB (0.45) | POLBFOLH1MEN1KMT2AGAA | |
| SCHEMBL28670835 | 0.87 | FOLH1 (0.50) | POLBFOLH1SMN1; SMN2TGM2RRM1 | |
| SCHEMBL28670837 | 0.87 | FOLH1 (0.50) | POLBFOLH1SMN1; SMN2TGM2RRM1 | |
| SCHEMBL15302107 | 0.82 | FOLH1 (0.47) | FOLH1SMN1; SMN2TGM2 | |
| SCHEMBL21952377 | 0.81 | FOLH1 (0.62) | FOLH1SMN1; SMN2KDM4E | |
| SCHEMBL16556662 | 0.81 | FOLH1 (0.62) | FOLH1SMN1; SMN2KDM4E | |
| SCHEMBL26830774 | 0.80 | FOLH1 (0.57) | FOLH1 | |
| SCHEMBL30265421 | 0.80 | MEN1 (0.65) | POLBMEN1KMT2AGAAALDH1A1 | |
| SCHEMBL16263610 | 0.80 | MEN1 (0.65) | POLBMEN1KMT2AGAAALDH1A1 | |
| SCHEMBL25356845 | 0.79 | FOLH1 (0.45) | FOLH1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090258381-A1 | Methods for Determining the Cleavability of Substrates | FORSCHUNGSZENTRUM BORSTEL (DE) | 2009-10-15 | — | — | US | disclosed |
| US-20090104633-A1 | Kit for Highly Sensitive Detection Assays | VYZKUMNY USTAV VETERINARNIHO LEKARSTVI (CZ) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258381-A1 | Methods for Determining the Cleavability of Substrates | CTSF, ADAM17, ADAM10 | POLB 2185/4885FOLH1 135/4885MEN1 2325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.